March 29, 2017
Guerbet reports €10M less profit for 2016
Guerbet, a global specialist in contrast agents and solutions for medical imaging, has published its consolidated and audited annual results for 2016.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
March 29, 2017
Plasticell makes deal with two Singapore research centers
Plasticell, a developer of stem cell technologies and cell-based therapies, has signed agreements with the Agency for Science, Technology and Research (A*STAR) and the Nanyang Technological University (NTU) to progress its therapeutic stem cell pipeline.
March 29, 2017
Port Erin Biopharma reports €0.5M profit for second half of 2016
Port Erin Biopharma Investments Limited has reported financial results for the six-month period ending 31 December 2016.
March 28, 2017
Milner Therapetucis Institute, Elysium Health partner up in developing preventive medicines
The Milner Therapeutics Institute is partnering up with Elysium Health to the Milner Therapeutics Consortium.
March 28, 2017
Xbrane Biopharma to deliver its cancer drug to Middle East
Xbrane Biopharma, a commercial phase Swedish biopharmaceutical company specialized in biosimilars and long acting injectables, has delivered its first batch of Spherotide to its partner in the Middle East to a value of €0.7 million.
March 28, 2017
Sinclair Pharma halves loss in 2016
Sinclair Pharma has reported €18.8 million loss for 2016 which represents decrease comparing last years loss of €32.7 million.
March 28, 2017
Amryt kicks off third phase of skin disorder treatment AP101
Amryt has begun with “EASE”, the Phase 3 clinical trial of AP101, its lead drug candidate, which offers a potential treatment for a rare genetic skin disorder that causes fragile skin.
March 27, 2017
Inventiva reports loss for 2016 due to R&D activities
Inventiva, a biopharmaceutical company developing innovative therapies, particularly to treat fibrosis, has reported its financial results for the year ended December 31, 2016.
March 27, 2017
Bioventix’s increases profit in second half of 2016
Bioventix, a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, has reported unaudited interim financial results for the six-month period ending 31 December 2016.
March 27, 2017
Amryt finds new CCO in Aegerion Pharmaceuticals after former one leaves
Amryt, the pharmaceutical company focused on treatments for rare and orphan diseases, has appointed David Allmond as Chief Commercial Officer in a non-board capacity, with effect from 3 April 2017.